SE9902989D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE9902989D0
SE9902989D0 SE9902989A SE9902989A SE9902989D0 SE 9902989 D0 SE9902989 D0 SE 9902989D0 SE 9902989 A SE9902989 A SE 9902989A SE 9902989 A SE9902989 A SE 9902989A SE 9902989 D0 SE9902989 D0 SE 9902989D0
Authority
SE
Sweden
Prior art keywords
hmw
maa
cells
epitope
displayed
Prior art date
Application number
SE9902989A
Other languages
Swedish (sv)
Inventor
Thomas N Brodin
Lennart G Ohlsson
M Jesper Tordsson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE9902989A priority Critical patent/SE9902989D0/en
Publication of SE9902989D0 publication Critical patent/SE9902989D0/en
Priority to AU68837/00A priority patent/AU762240B2/en
Priority to NZ517132A priority patent/NZ517132A/en
Priority to PCT/SE2000/001597 priority patent/WO2001014884A1/en
Priority to CA002381099A priority patent/CA2381099A1/en
Priority to EP00957184A priority patent/EP1206702A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

An epitope of high molecular weight melanoma associated antigen (HMW-MAA) displayed on the surface of human cells but not cells from Macaca fascicularis is described, said epitope a) having the ability of being specifically blocked by and specifically block a binding structure which recognizes HMW-MAA, b) being displayed on the surface of human cells but not cells from Macaca fascicularis, and c) having a normal tissue distribution pattern which is more restricted than that of other known epitopes of HMW-MAA. There is also described a binding structure and antibodies recognizing target structures of said antigen, pharmaceutical compositions and vaccines as well as methods of using said epitopes and antibodies in diagnostic and therapeutic methods related to human malignant diseases.
SE9902989A 1999-08-24 1999-08-24 Novel compounds SE9902989D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE9902989A SE9902989D0 (en) 1999-08-24 1999-08-24 Novel compounds
AU68837/00A AU762240B2 (en) 1999-08-24 2000-08-22 Melanoma associated antigen (HMW-MAA) defined by a monoclonal antibody
NZ517132A NZ517132A (en) 1999-08-24 2000-08-22 Melanoma associated antigen (HMW-MAA) defined by a monoclonal antibody
PCT/SE2000/001597 WO2001014884A1 (en) 1999-08-24 2000-08-22 Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody
CA002381099A CA2381099A1 (en) 1999-08-24 2000-08-22 Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody
EP00957184A EP1206702A1 (en) 1999-08-24 2000-08-22 Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902989A SE9902989D0 (en) 1999-08-24 1999-08-24 Novel compounds

Publications (1)

Publication Number Publication Date
SE9902989D0 true SE9902989D0 (en) 1999-08-24

Family

ID=20416736

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9902989A SE9902989D0 (en) 1999-08-24 1999-08-24 Novel compounds

Country Status (6)

Country Link
EP (1) EP1206702A1 (en)
AU (1) AU762240B2 (en)
CA (1) CA2381099A1 (en)
NZ (1) NZ517132A (en)
SE (1) SE9902989D0 (en)
WO (1) WO2001014884A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10328121A1 (en) * 2003-06-23 2005-02-03 Biolife Science Forschungs- und Entwicklungs-GbmH Passive immunotherapy for malignant melanoma
SE0402025D0 (en) 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
AT502292B1 (en) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology MELANOMA DIAGNOSIS
CN118420712A (en) * 2023-02-01 2024-08-02 上海健信生物医药科技有限公司 Trispecific antibody technical platform and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
SE9700291D0 (en) * 1997-01-31 1997-01-31 Pharmacia & Upjohn Ab Selection method and prodcts resulting therefrom

Also Published As

Publication number Publication date
CA2381099A1 (en) 2001-03-01
WO2001014884A1 (en) 2001-03-01
EP1206702A1 (en) 2002-05-22
NZ517132A (en) 2003-10-31
AU6883700A (en) 2001-03-19
AU762240B2 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
Livingston et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside
IN2012DN00313A (en)
AU768002B2 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
CA2523032A1 (en) Vaccines for cancer therapy
DK1187629T3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2004067023A3 (en) Survivin-derived peptides and use thereof
NO20011586D0 (en) New methods of therapeutic vaccination
Fernandez-Tejada et al. Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol
TW200604208A (en) Antibodies to angiogenesis inhibiting domains of CD148
CN108348618A (en) Adenine conjugate compounds and its purposes as vaccine adjuvant
WO2004012681A3 (en) Cancer vaccines containing epitopes of oncofetal antigen
CA2360382A1 (en) Use of antibodies for the vaccination against cancer
DE69637571D1 (en) COMPOSITION AND METHOD FOR REINFORCING THE IMMUNE RESPONSE OF ANTIGEN-PRESENTING CELLS
Lin et al. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice
JP2002534481A5 (en)
Quan Jr et al. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m.
SE9902989D0 (en) Novel compounds
AU5097393A (en) Stimulation of an antitumor t-cell response using anti-idiotypic antibodies
HUP0400698A2 (en) Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
TR200401267T4 (en) New uses of antibodies as vaccines.
Hong et al. A vaccine for hypertension based on peptide AngI-R: a pilot study
DE60313437D1 (en) MHC CLASS I PEPTIDEPITOPES OF HUMAN TUMOR ASSOCIATED ANTIGEN 5T4
ATE466879T1 (en) MHC CLASS II 5T4 ANTIGEN PEPTIDE EPITOPES
WO2001068677A3 (en) Derivatives of breast canacer antigen her-2 for therapeutical use